Immunocore Holdings PLC Sponsored ADR ( IMCR - Free Report ) shares ended the last trading session 6.9% higher at $60.81. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 3.5% loss over the past four weeks. Share price has been rising consistently since the onset of this week as multiple Wall Street analysts have rated the stock with a "Buy" recommendation. Earlier this week, Immunocore also announced preliminary net pre-product sales of around $50 million in fourth-quarter 2022, indicating around 25% quarter over quarter growth. This company is expected to post quarterly loss of $0.08 per share in its upcoming report, which represents a year-over-year change of +93.4%. Revenues are expected to be $49.24 million, up 453.3% from the year-ago quarter.